PureTech Share News (PRTC)
PRTC Share
PRTC Share
PRTC Share
PRTC Share
PRTC
PRTC Share
PRTC Level 2
PRTC Live
PRTC Broker
PRTC Directors
PRTC Financial
PRTC
PRTC Short
PRTC
Last checked at -
(Sharecast News) - Clinical stage biotherapeutics company PureTech Health announced on Tuesday that its founded company Gelesis has received approval to market 'Plenity', a novel weight-loss treatment, in Europe.
Read more
UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work
Read more(Sharecast News) - PureTech Health announced plans on Thursday to advance its wholly-owned clinical-stage product candidate 'LYT-100', or deupirfenidone, as a potential treatment for serious respiratory complications, including inflammation and fibrosis, that persist following the resolution of Covid-19 infection.
Read moreUK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield
Read more(Sharecast News) - Clinical stage biotechnology company PureTech Health said on Tuesday that it had received $45m from the sale of 555,500 shares of its founded entity Karuna Therapeutics.
Read moreUK DIRECTOR DEALINGS SUMMARY: Novacyt Chair And CEO Step In To Buy
Read morePureTech Health Swings To Annual Profit On Exceptional Gains
Read more(Sharecast News) - Clinical-stage biotherapeutics company Puretech Health posted weaker full-year revenues and a widened operating loss on Thursday and also noted it was yet to see any impact to ongoing work as a result of the Covid-19 outbreak.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read morePureTech Health Doses First Patient In Phase 1 LYT-100 Study
Read more(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that the first participant has been dosed in a clinical study of 'LYT-100', its wholly-owned product candidate for the potential treatment of lymphoedema and other fibrotic conditions.
Read morePureTech Health Affiliate Akili Posts Encouraging ADHD Study Results
Read more(Sharecast News) - TT Electronics: Jefferies downgrades to hold with a target price of 265p.
Read more(Sharecast News) - Clinical stage biotech company PureTech Health said it had sold 2.1m shares of its affiliate Karuna Therapeutics for $200m.
Read morePureTech Health Unit Akili's AKL-T01 Study Achieves Primary Endpoint
Read more
Last checked at